A Study With an Increased Dose Step in Patients That Have Previously Received Placebo or sNN0031.
Status:
Terminated
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and tolerability of a dose of 95μg sNN0031
after intracerebroventricular administration to patients with Parkinson's disease